CMTA-STAR has awarded $354,826 to support a clinical trial evaluating L-serine in patients with Hereditary Sensory Neuropathy 1, a rare form of CMT. Led by Dr. Mary Reilly at University College London, the study will assess disease progression using MRI muscle fat fraction as a primary outcome measure, advancing clinical trial readiness for inherited neuropathies.
Simply CMT
More From Simply CMT
-
CMTA Camp Footprint Launches Fellowship with ACA Grant
A new year-long program helps campers bring the confidence of camp home
-
Walking With CMT: How Strength, Movement, and Sensation Work Together to Improve Stability
For people living with CMT, changes in muscle strength, joint motion, and sensory feedback can make walking feel less stable over time.